Evidence map›Paper›PMID 23362135›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2013

Tumor localization and biochemical response to cure in tumor-induced osteomalacia.

William H Chong, Panagiota Andreopoulou, Clara C Chen, James Reynolds, Lori Guthrie, Marilyn Kelly, Rachel I Gafni, Nisan Bhattacharyya, Alison M Boyce, Diala El-Maouche and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 2 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Burosumab for the Treatment of Tumor-Induced Osteomalacia.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021
    Trial
  4. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. A nomogram for predicting surgery outcome of tumor-induced osteomalacia: a case-control study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 2 countries.

William H ChongSkeletal Clinical Studies Unit, Craniofacial and Skeletal Disease Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.
Panagiota Andreopoulou
Clara C Chen
James Reynolds
Lori Guthrie
Marilyn Kelly
Rachel I Gafni
Nisan Bhattacharyya
Alison M Boyce
Diala El-Maouche
Diana Ovejero Crespo
Richard Sherry
Richard Chang
Felasfa M Wodajo
Gad B Kletter
Andrew Dwyer
Michael T Collins
National Institute of Dental and Craniofacial Research · USNational Institutes of Health Clinical Center · USNational Institutes of Health · USAlbert Einstein College of Medicine · USCenter for Global Health · USInstitute of Musculoskeletal Science & Education (United States) · USNational Cancer Institute · USSwedish Medical Center · US

Funding

Skeletal Disorders and Mineral Homeostasis SectionZIADE000649 · NIDCR · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · PI COLLINS, MICHAEL · 2009 to 2025
$32.8M
The NIH Inter-Institute Training Program in Endocrinology, Diabetes & MetabolismZIEDK075100 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI MUNIYAPPA, RANGANATH · 2009 to 2025
$18.0M
Clinical Studies Of Skeletal DiseasesZ01DE000649 · NIDCR · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · PI COLLINS, MICHAEL · 1995 to 2008
$2.7M
Treatment of Deep Vein Thrombosis of the Lower Extremities w/Low Dose AlteplaseZIACL010343 · CLC · CLINICAL CENTER · PI CHANG, RICHARD T · 2009 to 2014
$0k
Intramural NIH HHS Z01 DE000649
6 · The paper itself

Abstract

Tumor-induced osteomalacia (TIO) is a rare disorder of phosphate wasting due to fibroblast growth factor-23 (FGF23)-secreting tumors that are often difficult to locate. We present a systematic approach to tumor localization and postoperative biochemical changes in 31 subjects with TIO. All had failed either initial localization, or relocalization (in case of recurrence or metastases) at outside institutions. Functional imaging with ¹¹¹Indium-octreotide with single photon emission computed tomography (octreo-SPECT or SPECT/CT), and ¹⁸fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT) were performed, followed by anatomic imaging (CT, MRI). Selective venous sampling (VS) was performed when multiple suspicious lesions were identified or high surgical risk was a concern. Tumors were localized in 20 of 31 subjects (64.5%). Nineteen of 20 subjects underwent octreo-SPECT imaging, and 16 of 20 FDG-PET/CT imaging. Eighteen of 19 (95%) were positive on octreo-SPECT, and 14 of 16 (88%) on FDG-PET/CT. Twelve of 20 subjects underwent VS; 10 of 12 (83%) were positive. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were as follows: sensitivity = 0.95, specificity = 0.64, PPV = 0.82, and NPV = 0.88 for octreo-SPECT; sensitivity = 0.88, specificity = 0.36, PPV = 0.62, and NPV = 0.50 for FDG-PET/CT. Fifteen subjects had their tumor resected at our institution, and were disease-free at last follow-up. Serum phosphorus returned to normal in all subjects within 1 to 5 days. In 10 subjects who were followed for at least 7 days postoperatively, intact FGF23 (iFGF23) decreased to near undetectable within hours and returned to the normal range within 5 days. C-terminal FGF23 (cFGF23) decreased immediately but remained elevated, yielding a markedly elevated cFGF23/iFGF23 ratio. Serum 1,25-dihydroxyvitamin D₃ (1,25D) rose and exceeded the normal range. In this systematic approach to tumor localization in TIO, octreo-SPECT was more sensitive and specific, but in many cases FDG-PET/CT was complementary. VS can discriminate between multiple suspicious lesions and increase certainty prior to surgery. Sustained elevations in cFGF23 and 1,25D were observed, suggesting novel regulation of FGF23 processing and 1,25D generation.

Indexed as

Bone NeoplasmsOsteomalaciaPositron-Emission TomographyTomography, Emission-Computed, Single-PhotonAdolescentAdultAgedCalcitriolFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFluorodeoxyglucose F18Follow-Up StudiesHumansMaleCalcitriolFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsFluorodeoxyglucose F18indium-111-octreotideNeoplasm ProteinsOctreotideRadiopharmaceuticals

Identifiers

PMID23362135
PMCPMC3900247
OpenAlexW1877345851

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.